Months after a monstrous blowup, a closely watched biotech sets its sights on gene therapy – STAT
STAT |
Months after a monstrous blowup, a closely watched biotech sets its sights on gene therapy
STAT The pivot to gene therapy is a chance for Ramaswamy, Axovant's chairman, to write a second act for his neuroscience company. Cheruvu said the Oxford BioMedica deal represents “a strategic shift” for the company, an effort “to push Axovant in the … Axovant Licenses Investigational Gene Therapy for Parkinson's Disease from Oxford BioMedica and Announces Key … Axovant pivots with new gene therapy, Spark co-founder as CTO |
